News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Good Salary, Nice Bonus—But Why Did Biotech Mogul David Hung Gamble On Axovant (AXON)?



4/11/2017 7:18:05 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
One day into his new job as CEO of Axovant $AXON, you might say that David Hung is earning his pay.

The biotech’s stock ended up 23% as investors cheered the return of the legendary biotech dealmaker, not so long after his crowning achievement: A $14 billion buyout for Medivation.

That boost added $340 million to the market cap, which Axovant’s Vivek Ramaswamy — one of the savviest players to ever make the leap from hedge fund to biotech — immediately sought to cash in on with a $100 million shelf offering.

Read at News Release


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES